Topic: Antiviral

Media reports describe surging demand for COVID-19 tests ahead of Christmas as people seek to gather safely. The FDA grants emergency use authorization for Pfizer's antiviral pill, which is touted as 90% effective. The hosts criticize the "psychological operation" of encouraging healthy people to stand in long lines for tests and mock a Canadian PSA featuring a "vaccinated" Rudolph the Red-Nosed Reindeer.

Dr. Jen Ashton reports on ABC News about the third U.S. case of bird flu, noting the patient had a cough but was not hospitalized. She informs viewers that the national stockpile already contains effective antivirals and a vaccine that can be ramped up quickly. The hosts mock the repetitive "should we be concerned?" framing used across different news networks.

The discussion shifts to antiviral treatments like Tamiflu and Relenza, which are noted for their effectiveness in stopping flu progression if taken early. It is observed that these treatments are rarely mentioned in mainstream news reports compared to vaccines. The segment also covers the process of how flu strains are selected for vaccines based on data from Australia.

The UK's National Health Service (NHS) is facing a potential meltdown, leading to calls for the return of COVID-era masking and social distancing. In Wales, health chiefs have advised citizens to avoid "specific activities" like long runs to reduce the burden on emergency departments. Some scientists, including Geert Vanden Bossche, argue that mass vaccination during a pandemic has created a breeding ground for more virulent variants.

Immunologist Geert van den Bosch warns that mass vaccination is creating a breeding ground for more virulent COVID-19 variants. He advises those vaccinated early in the pandemic to seek antivirals, as he believes their innate immunity has been compromised. The discussion also notes an unusual increase in bulk orders for youth-sized caskets.

Reports from the Boston Globe indicate that patients using Pfizer's antiviral pill, Paxlovid, are experiencing a "rebound" of COVID-19 symptoms after completing the treatment. The phenomenon raises questions about the long-term efficacy of the antiviral as a replacement for other treatments.

White House Press Secretary Jen Psaki warned that federal programs for COVID-19 testing, monoclonal antibodies, and antiviral treatments will be scaled back if Congress does not provide $22.5 billion in emergency funding. The administration claims that the lack of funding will leave the U.S. unprepared for future variants. Critics view this as a political setup to blame Republicans for any future resurgence of the virus after funding was stripped from a recent spending bill.

The White House releases a 96-page COVID-19 preparedness plan, introducing a "test-to-treat" initiative that provides immediate access to Pfizer's antiviral pills. The plan includes aggressive monitoring for new variants and faster approval processes for updated vaccines. The hosts view this as a permanent expansion of pharmaceutical influence and government surveillance.

The FDA granted emergency use authorization for Pfizer's antiviral pill, Paxlovid, which clinical studies suggest is nearly 90% effective against severe illness. The Biden administration has committed to purchasing 10 million doses, though initial supply will be limited during the production ramp-up.

An FDA advisory committee voted 13-10 to recommend EUA for Merck's antiviral pill, Molnupiravir, despite concerns over its 34% efficacy and potential risks during pregnancy. The discussion contrasts the approval of this expensive pill with the suppression of cheaper alternatives like ivermectin.

Merck reported a strong fiscal quarter, exceeding expectations by $1 billion, driven by growth in its oncology business and a 68% increase in Gardasil sales. CEO Robert Davis discussed the upcoming launch of Molnupiravir, an oral antiviral pill intended for home use, with an advisory committee meeting scheduled for late November. Merck plans to produce 10 million courses of the drug by the end of the year, with pricing estimated by some analysts at up to $2,000 per course.

Pfizer is running commercials for a new oral antiviral pill designed to act as a protease inhibitor to stop COVID-19 replication. Critics point out that existing, low-cost drugs like hydroxychloroquine also function as protease inhibitors, leading to accusations that Pfizer is simply rebranding old science for profit. The pharmaceutical giant is positioning "science" as the ultimate winner in its marketing campaigns for these new daily treatments.

Dr. Pierre Kory argues that Ivermectin is a highly effective, low-cost treatment for COVID-19 that is being ignored in favor of expensive, patented drugs. He claims that over 100,000 American lives could have been saved if the NIH had adopted Ivermectin protocols earlier.

Oxford University has begun testing the anti-parasitic drug ivermectin as a potential COVID-19 treatment for non-hospital settings. This follows a period where the drug was largely dismissed by the medical establishment. Additionally, a new antiviral pill, AT-527, which was originally developed for Hepatitis C, is currently in late-stage clinical trials for use against the coronavirus.

The World Health Organization (WHO) has officially removed Remdesivir from its list of recommended COVID-19 treatments. The drug, which was heavily promoted by mainstream media and health agencies as a primary antiviral against the virus, has faced ongoing questions regarding its actual efficacy and safety profile.

Pfizer begins testing an oral antiviral pill to treat COVID-19, utilizing a process similar to HIV treatments. This development is compared to Dr. Anthony Fauci's historical work with AZT during the AIDS crisis. Meanwhile, Krispy Kreme offers a free donut daily to vaccinated individuals, a marketing tactic viewed as a way to drive demand through corporate incentives.

A new oral antiviral drug called Molnupiravir is being positioned as a "Tamiflu for COVID," with early Phase 2 data showing it clears the virus in five days. Dr. Fauci and other researchers suggest that oral drugs are necessary to suppress the virus, similar to treatments for HIV and Hepatitis C. Critics argue that existing, cheaper alternatives like Ivermectin are being ignored in favor of expensive new pharmaceutical products like "COVID-27" preparations.

Dr. Pierre Kory testified before the Senate, claiming that ivermectin has a "miraculous impact" on COVID-19 transmission and mortality. Representing the Front Line COVID-19 Critical Care Alliance, Kory cited mountains of data from randomized controlled trials showing the drug's effectiveness as a prophylactic. He expressed frustration that the NIH has not updated its recommendations to include repurposed drugs.

Research into COVID-19 therapeutics suggests that the active metabolite in Remdesivir, GS-441524, is also known as a feline antiviral. Additionally, studies indicate that melatonin may inhibit the cytokine storm induced by COVID-19. The hosts discuss the common household use of melatonin for sleep and jet lag.

The discussion touches on the potential for vaporized propylene glycol, a common ingredient in vape juice, to act as a disinfectant for the lungs. While historically linked to slowing the spread of influenza, its effectiveness against the coronavirus remains unproven.